Trial Profile
A study evaluating KY1044 in advanced solid cancers
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Alomfilimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 25 Jul 2018 New trial record
- 28 Jun 2018 According to a Kymab media release, the trial initiation expected 1H 2019.